DOI: https://doi.org/10.36347/sajp.2026.v15i10.004

Pages: 242-248

Polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome) commonly declares itself during adolescence, and its metabolic trajectory is substantially established by the time adult criteria are met. Depletion of short-chain fatty acid-producing gut bacteria is a reproducible feature of the adult syndrome, and butyrate acts on several of the pathways that define it, including insulin sensitivity, enteroendocrine signalling, intestinal barrier function and ovarian granulosa-cell inflammation. Whether restoring or preserving these organisms early can alter the course of the syndrome has not been examined. This review sets out the case for treating adolescence as the intervention window and documents how little evidence exists within it: a systematic review of the gut microbiome in youth with PMOS screened 178 records and included four studies. We summarise what those and adjacent studies show, including the finding that microbiota alterations are present in adolescent girls independently of obesity, and that an insulin-sensitising combination normalised a microbiota feature that an oral contraceptive did not. We then set out the principal preclinical result supporting a preventive strategy, in which a sustained-release butyrate preparation given from weaning prevented the development of the phenotype in prenatally androgenised mice, and the contrasting result in which bolus sodium butyrate given to animals with established disease was not protective. Together these define timing and delivery as the variables that matter. We conclude with the design requirements for a prevention trial and the diagnostic caveats that constrain it. We situate butyrate delivery within postbiotic and microbial-metabolite strategies and argue that formulation, not dose, is the variable that separated the one preventive success from the one harmful result.